Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook

Corcept Therapeutics' Chief Development Officer William Guyer sold 20,000 shares worth $1.9 million on July 7, 2026, under a pre-scheduled Rule 10b5-1 trading plan established in November 2024. Despite liquidating 83% of his direct holdings, Guyer retains 130,000 stock options. The sale comes as Corcept achieved FDA approval for Lifyorli (cortisol-blocking ovarian cancer drug) ahead of schedule and raised full-year revenue guidance to $950 million-$1.05 billion, though the company posted a $31.8 million loss in Q1 due to heavy launch spending.